REGN US Equity

746.54USD▲ 0.94%

REGENERON PHARMACEUTICALS, INC. (REGN): análisis fundamental y valoración

REGENERON PHARMACEUTICALS, INC. cotiza a 746.54 USD y tiene una capitalización bursátil de $76.9B. Datos fundamentales de la SEC EDGAR con hasta 20 años de histórico, insiders, institucionales y valoración DCF.Más empresas del sector Salud

Price History

Perfil

BolsaNasdaqPaísUnited StatesEmpleados15,410Beta0.19Web↗ www.regeneron.com

Regeneron Pharmaceuticals, Inc. discovers, invents, develops, manufactures, and commercializes medicines to treat various diseases worldwide. The company develops product candidates to treat eye, allergic and inflammatory, cardiovascular, metabolic, neurological, infectious, and rare diseases; and cancer, hematologic c…

Múltiplos de Valoración

P/E (Annual)

17.1×

P/E (TTM)

—

P/FCF (Annual)

18.8×

P/FCF (TTM)

—

EV/EBITDA

18.4×

EV/Revenue

5.3×

P/Sales

5.4×

P/Book

2.5×

Rentabilidad (Último Anual)

Gross Margin

—

Operating Margin

24.9%

Net Margin

31.4%

FCF Margin

28.4%

ROE

14.4%

ROCE

9.9%

ROA

11.1%

Effective Tax Rate

13.9%

Métricas TTM

Revenue TTM

—

Gross Profit TTM

—

Operating Income TTM

—

Net Income TTM

—

FCF TTM

—

EPS TTM

—

Quarters Used

—

TTM Period

—

Solidez del Balance

Net Debt

−$1.1B

Net Debt / EBITDA

-0.3×

Debt / Equity

0.06

Current Ratio

4.13

Interest Coverage

91.5×

Working Capital

$13.7B

Book Value / Share

303.6

Net Debt / Share

-11

Crecimiento (YoY)

Revenue YoY

+1.0%

Net Income YoY

+2.1%

FCF YoY

+11.3%

EPS Diluted YoY

+8.2%

Retorno al Accionista

Dividend Yield

0.5%

Payout Ratio

8.2%

FCF / Share

39.63

CapEx % Revenue

6.3%

Rev / Employee

930,752

Próximos Eventos

Ex-Dividendo

2026-08-18

Pago Dividendo

2026-08-31

Historial EPS

Periodo	2026-10	2026-07	2026-04	2026-01
Real	—	$14.29	$9.47	$11.44
Estimado	$16.03	$10.21	$8.90	$10.75
Sorpresa	—	+40.0%	+6.4%	+6.4%

Empresas similares

Smart Money

vs Sector: Healthcare (1130 empresas)

Métrica	REGN	Mediana Sector	Δ
Gross Margin	—	57.0%	—
Operating Margin	24.9%	-38.6%	+63.6%
Net Margin	31.4%	-33.6%	+65.0%
FCF Margin	28.4%	-13.9%	+42.3%
ROE	14.4%	-40.4%	+54.8%
ROA	11.1%	-32.0%	+43.1%
Current Ratio	4.13	2.84	+1.29
Debt / Equity	0.06	0.28	-0.22

Scoring Fundamental

Piotroski F-Score

5/ 8Moderado

✓F1ROA positivo (rentabilidad activos)

✓F2Flujo caja operativo positivo

✗F3ROA mejora vs año anterior

✓F4Calidad de beneficios (OCF > ROA)

✓F5Apalancamiento baja

✗F6Liquidez mejora (current ratio)

✓F7Sin dilución accionarial

✗F8Margen bruto mejora

✗F9Rotación activos mejora

Altman Z-ScoreZona Segura

7.24

x1_working_capital0.337

x2_retained_earnings0.883

x3_ebit0.088

x4_market_equity8.263

x5_sales0.354

>2.99 segura · 1.81–2.99 gris · <1.81 riesgo

Capital Allocation

6/ 8Sólida

✓FCF+Free cash flow positivo

✓FCFmMargen FCF > 10%

✓DilucSin dilución significativa (< 2%/año en 3 años)

✓Rev↑Revenue CAGR 3 años > 5%

✗ROCERetorno sobre capital empleado > 10%

✓DeudaDeuda neta/EBITDA < 3× (o posición de caja neta)

✗Mg↑Margen operativo ≥ hace 2-3 años (tolerancia -2pp)

✓Inv.R&D + Capex > 3% de revenue (reinversión en el negocio)

Histórico Piotroski F-Score

Histórico de Múltiplos

Periodo

2026-10

2026-07

2026-04

2026-01

Real

—

$14.29

$9.47

$11.44

Estimado

$16.03

$10.21

$8.90

$10.75

Sorpresa

—

+40.0%

+6.4%

Métrica

REGN

Mediana Sector

Gross Margin

—

57.0%

—

Operating Margin

24.9%

-38.6%

+63.6%

Net Margin

31.4%

-33.6%

+65.0%

FCF Margin

28.4%

-13.9%

+42.3%

ROE

14.4%

-40.4%

+54.8%

ROA

11.1%

-32.0%

+43.1%

Current Ratio

4.13

2.84

+1.29

Debt / Equity

0.06

0.28

-0.22